Current standards and future directions in treatment of follicular lymphoma

Keyphrases

• Follicular Lymphoma 100%
• Rituximab 100%
• Relapsed Disease 75%
• Response Rate 50%
• Monoclonal Antibody 50%
• Chemotherapy 50%
• Bortezomib 50%
• Lenalidomide 50%
• Bendamustine 50%
• Tositumomab 50%
• High Tumor Burden 50%
• Rituximab Maintenance 50%
• Prednisone 25%
• Twice Daily 25%
• Initial Treatment 25%
• Survival Benefit 25%
• First-line Therapy 25%
• Novel Agents 25%
• Phase II Trial 25%
• Radioimmunotherapy 25%
• Heavily Pretreated Patients 25%
• Rituximab-refractory 25%
• Doxorubicin 25%
• Subsequent Therapy 25%
• Cyclophosphamide 25%
• New Agents 25%
• Pretreated Patients 25%
• Refractory Disease 25%
• Retreatment 25%
• Low Tumor Burden 25%
• High Response Rate 25%
• Weekly Regimen 25%
• Single-agent Therapy 25%
• Oral Therapy 25%
• Antigenic Specificity 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Follicular Lymphoma 100%
• Rituximab 100%
• Neoplasm 42%
• Recurrent Disease 42%
• Chemotherapy 28%
• Bortezomib 28%
• Monoclonal Antibody 28%
• Lenalidomide 28%
• Bendamustine 28%
• Tositumomab 28%
• Prednisone 14%
• Doxorubicin 14%
• Iodine-131 14%
• Cyclophosphamide 14%
• Vincristine 14%
• Diseases 14%